Landos Biopharma Inc reports results for the quarter ended in March - Earnings Summary

Landos Biopharma

16/05/2022 13:00

* Landos Biopharma Inc  LABP.OQ  reported a quarterly
adjusted
loss of 37 cents​​ per share for the quarter ended in March. The
mean expectation of five analysts for the quarter was for a loss
of 35 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Landos Biopharma Inc's reported EPS for the quarter was a
loss
of 37 cents​.
    * The mean earnings estimate of analysts had fallen by
about 5.1%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Landos Biopharma Inc shares had fallen by 54.1% this
quarter and
lost 85.9% so far this year.
    * The company reported a quarterly loss of $14.86 million.
    * Wall Street's median 12-month price target for Landos
Biopharma
Inc is $16.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 16 at 12:00 p.m.  ​All
figures in US dollars unless otherwise stated